Public Health Vaccines LLC
Public Health Vaccines (PHV) is a privately-held biotechnology company dedicated to developing vaccines for the prevention and control of global Emerging Infectious Diseases. With years of experience in vaccine and medical countermeasure products, PHV's mission is to develop and advance novel vaccines that address significant global public health threats. The company leverages its expertise to deliver potentially life-saving medical countermeasures aligned with the evolving global landscape.
Industries
Nr. of Employees
small (1-50)
Public Health Vaccines LLC
Products
Marburg virus vaccine candidate (rVSV-based)
A single-dose vaccine candidate against Marburg virus developed on a recombinant VSV-type replicating viral vector platform; preclinical efficacy in primate models and advanced development under a government advanced development contract.
Nipah virus vaccine candidate (rVSV-based)
A live, attenuated single-dose vaccine candidate against Nipah virus using a vesicular stomatitis virus vector; funded to progress through Phase 2 clinical testing under a partnership with a global epidemic preparedness funder.
Sudan ebolavirus (SUDV) vaccine candidate (rVSV-based)
A vaccine candidate targeting Sudan ebolavirus generated on a recombinant VSV-type vector platform; constructed using starting materials from a national public health laboratory and mirroring platform design used for other filovirus vaccines.
Marburg virus vaccine candidate (rVSV-based)
A single-dose vaccine candidate against Marburg virus developed on a recombinant VSV-type replicating viral vector platform; preclinical efficacy in primate models and advanced development under a government advanced development contract.
Nipah virus vaccine candidate (rVSV-based)
A live, attenuated single-dose vaccine candidate against Nipah virus using a vesicular stomatitis virus vector; funded to progress through Phase 2 clinical testing under a partnership with a global epidemic preparedness funder.
Sudan ebolavirus (SUDV) vaccine candidate (rVSV-based)
A vaccine candidate targeting Sudan ebolavirus generated on a recombinant VSV-type vector platform; constructed using starting materials from a national public health laboratory and mirroring platform design used for other filovirus vaccines.
Services
R&D of vaccine candidates against emerging infectious diseases using recombinant viral vector platforms, including preclinical evaluation and preparation for clinical testing.
Management and execution of advanced development activities under government contracts and partnerships, including coordination with funders and subcontractors.
R&D of vaccine candidates against emerging infectious diseases using recombinant viral vector platforms, including preclinical evaluation and preparation for clinical testing.
Management and execution of advanced development activities under government contracts and partnerships, including coordination with funders and subcontractors.
Expertise Areas
- Viral-vector vaccine development
- Filovirus and emerging infectious disease vaccines
- Clinical trial management (Phase 1–2)
- Nonclinical/animal model efficacy studies
Key Technologies
- Recombinant vesicular stomatitis virus (rVSV-type) vector platform
- Live attenuated single-dose vaccine design
- Nonhuman primate efficacy models
- cGMP manufacturing and technology transfer
News & Updates
A promising vaccine candidate against Nipah is ready for mid-stage human trials in Bangladesh, where outbreaks occur annually. The trial is expected to launch in early 2026, and the vaccine (PHV02) will be among the first Nipah vaccine candidates to reach this stage.
PHV announced the start of its Phase 1 clinical trial to evaluate the safety and immunogenicity of its single-dose vaccine (PHV02) against Nipah virus.
PHV was awarded the first two options under its BARDA contract for the advanced development of its Marburg virus vaccine candidate.
CEPI partnered with PHV with a funding of up to US$43.6 million to develop and manufacture a Nipah virus vaccine.
PHV received a contract from BARDA for the advanced development of its Marburg virus vaccine candidate.
PHV entered into a license arrangement with the Public Health Agency of Canada to leverage the recombinant vesicular stomatitis virus (rVSV) platform to develop vaccines against Marburg virus and Sudan ebolavirus.
A promising vaccine candidate against Nipah is ready for mid-stage human trials in Bangladesh, where outbreaks occur annually. The trial is expected to launch in early 2026, and the vaccine (PHV02) will be among the first Nipah vaccine candidates to reach this stage.
PHV announced the start of its Phase 1 clinical trial to evaluate the safety and immunogenicity of its single-dose vaccine (PHV02) against Nipah virus.
PHV was awarded the first two options under its BARDA contract for the advanced development of its Marburg virus vaccine candidate.
CEPI partnered with PHV with a funding of up to US$43.6 million to develop and manufacture a Nipah virus vaccine.
PHV received a contract from BARDA for the advanced development of its Marburg virus vaccine candidate.
PHV entered into a license arrangement with the Public Health Agency of Canada to leverage the recombinant vesicular stomatitis virus (rVSV) platform to develop vaccines against Marburg virus and Sudan ebolavirus.